Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-ipilimumab PET biodistribution in metastatic melanoma during nivolumab + ipilimumab treatment
NL-OMON53144Recruiting
- Sponsor
- Vrije University Medical Center
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of ipilimumab, nivolumab and 89Zr-ipilimumab in melanoma, sponsored by Vrije University Medical Center. Primary endpoint: Primary endpoint: tumor uptake of 89Zr-ipilimumab. Started May 2017; status: recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NL-OMON53144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53144.